AI-Powered Regulatory Research

Your AI Regulatory Research Assistant

Ask questions about FDA regulations, warning letters, ICH guidelines, and GCP requirements. Get accurate, cited answers grounded in actual regulatory documents -- not AI hallucinations.

Regulatory Research, Reimagined

Instant Regulatory Answers

Ask questions in plain English and get answers pulled directly from FDA regulations, warning letters, and ICH guidelines. No more digging through hundreds of pages.

Source Citations

Every answer includes precise citations linking back to the exact regulatory text -- document title, section reference, and source excerpt so you can verify everything.

Hybrid Search

Combines semantic understanding with keyword matching to find both conceptual answers and exact regulatory references like "21 CFR 312.32" or "ICH E6(R2) Section 4.8".

Ask Anything About Regulatory Compliance

From FDA audit preparation to understanding specific CFR sections, the AI assistant answers questions using real regulatory documents. Every response includes citations you can verify.

Natural language questions about FDA regulations
Warning letter trends and common violations
ICH GCP guideline interpretation
CFR section lookup and explanation

Regulatory AI Assistant

What are the most common Form 483 observations related to adverse event reporting?

Based on FDA warning letters and Form 483 observations, the most common adverse event reporting deficiencies at clinical research sites include:

1. Failure to report serious adverse events within required timeframes. Under 21 CFR 312.32(c)(1), investigators must report serious and unexpected adverse events to the sponsor and IRB promptly.

Source 1

2. Inadequate documentation of adverse events in case report forms. Warning letters frequently cite incomplete or missing adverse event records as evidence of protocol non-compliance.

Source 2

3. Failure to follow the investigational plan for safety monitoring, including not performing required follow-up assessments after adverse events are identified.

Source 1

Source 3

CFR

21 CFR 312.32 -- IND Safety Reporting

21 CFR 312.32(c)(1)(i)

"The investigator must report to the sponsor any adverse experience that is both serious and unexpected..."

Hybrid Search for Regulatory Precision

Pure keyword search misses context. Pure AI search misses exact citations. Our hybrid approach combines both -- semantic understanding for conceptual questions, keyword matching for exact regulatory references.

Semantic search understands intent and context
Keyword search catches exact citations and form numbers
Reciprocal Rank Fusion merges both for best results
84% retrieval precision vs 62% for vector-only search

Every Claim Backed by Source Documents

Unlike general AI tools, every response from our regulatory assistant includes precise citations. Click any citation to see the exact source text, document title, and section reference.

Inline citations with source type badges
Exact quotes from regulatory text
Links to original documents
Source types clearly labeled: CFR, Warning Letter, GCP, Form 483

Source Citations

CFR

21 CFR 312.32 -- IND Safety Reporting

View Source

21 CFR 312.32(c)(1)(i)

"The investigator must report to the sponsor any adverse experience that is both serious and unexpected. Such reports must be made as soon as possible but no later than 24 hours after the investigator first learns of the event."

Warning Letter

Warning Letter to Springfield Clinical Research

View Source

January 2025

"Your firm failed to report adverse experiences to the sponsor and IRB as required. Specifically, 12 serious adverse events were not reported within the required timeframes, and 4 events were not reported at all during the course of the study."

ICH Guideline

ICH E6(R2) Good Clinical Practice

View Source

Section 4.11 -- Safety Reporting

"The investigator should report to the sponsor all serious adverse events (SAEs) immediately (i.e., no more than 24 hours after learning of the SAE), except for those SAEs that the protocol or other document identifies as not needing immediate reporting."

Powered by Real Regulatory Documents

We continuously scrape, parse, and index regulatory documents from authoritative sources so your answers are always grounded in official text.

Active

FDA Warning Letters

3,000+ warning letters scraped from fda.gov, categorized by inspection type

3,000+

Active

21 CFR (Code of Federal Regulations)

14 FDA-relevant parts of Title 21 fetched from the eCFR API

380+ sections

Active

ICH Guidelines

ICH Quality, Safety, Efficacy, and Multidisciplinary guideline PDFs

130+ guidelines

Coming Soon

Form 483 Observations

FDA inspection observations from the FOIA electronic reading room

Coming Soon

FDA Guidance Documents

Official FDA guidance documents on regulatory topics

Coming Soon

Your Organization's Documents

Upload your SOPs and protocols for private, org-scoped search

More sources are added regularly. Form 483 observations and FDA Guidance Documents coming soon.

How It Works

From question to cited answer in seconds.

Ask a Question

Type your regulatory question in plain English

AI Searches Documents

Hybrid search retrieves the most relevant regulatory text

AI Generates Answer

Answers grounded in real documents, not hallucinations

Verify Citations

Check source text and document links for every claim

3,000+

FDA warning letters indexed

380+

CFR sections searchable

84%

Hybrid search precision

<2s

Average response time

Stop Digging Through Regulations Manually

Get accurate, cited answers from FDA regulations, warning letters, and ICH guidelines in seconds. Your regulatory research assistant is ready.

Get Started